Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410653 | 0.85 | CYP19A1 (0.58) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL11248355 | 0.85 | CYP19A1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1HMOX2 | |
| SCHEMBL11239699 | 0.85 | CYP19A1 (0.61) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL11238973 | 0.84 | HMOX2 (0.64) | CYP19A1CYP11B1CYP11B2TBXAS1HMOX2 | |
| Hydrochloric Acid SCHEMBL407087 | 0.84 | CYP19A1 (0.57) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL10333093 | 0.84 | HMOX1 (0.49) | TBXAS1HMOX2 | |
| Hydrochloric Acid SCHEMBL11265743 | 0.84 | CYP19A1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL8805267 | 0.83 | CYP19A1 (0.63) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL9827059 | 0.82 | CYP19A1 (0.52) | CYP19A1CYP11B1CYP11B2HMOX2 | |
| SCHEMBL11242327 | 0.81 | LMNA (0.54) | CYP19A1TBXAS1HMOX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| EP-0709378-B1 | Aminoalkyloximes, a process for their preparation, their use as medicaments and intermediate compounds | AVENTIS PHARMA INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | CYP19A1 1303/4885CYP11B1 639/4885CYP11B2 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.